Founders-Angels Investing in Digital Health

Starting a digital health company is hard. Really hard.

And today, raising first capital is quite different and much harder compared to just a few years.

Enter – ‘founder-angels’.

There is a potential big double whammy here: ‘Initiation’ capital + tangible value add (experience, network, access).

Based on conversations with recently had with dozen of angels investing in early stage digital health, and a dedicated event we recently held, this piece will cover:

• Why founders become angels
• How to engage them
• What red flags will drive an immediate no
• Angels vs. VCs
• What current market conditions in digital health mean for Angels

Why Founders Become Angels

Consider the current ecosystem: according to Rock Health, more than 35% of early-stage digital health rounds now include at least one founder-angel investor. This isn’t a niche phenomenon anymore, it’s a structural change in the way capital gets allocated.

It isn’t just a market ‘requirement’ as more VCs are waiting for more validation before they invest. It is a situation driven also by the growing interest of founders to pursue angel investing in digital health. But why?

As a starter, as the industry matures, there are more experienced founders and more of them have the means to act as angels (namely, deploy 5-6 digit checks into >10 companies). There’s also the argument (sometimes justified, sometimes not) that having built before gives you pattern recognition. Some founders believe they can spot good teams slightly better than the average investor. Some have the investment track record to back that claim.

But it is not just about capital. There is a repeated theme among founders. They (usually) want to help their keen. For many, it simply means a lot of coffee and perhaps some video calls with entrepreneurs building in places they know. For some, putting an investment on top of that is actually easy. “I’ve already done most of the work – analyzing the business, getting to know the team, making some intros and seeing how they follow up on them, so deciding to invest is a very easy next step” as one said. “You believe you can offer tactical advice – on hiring, on fundraising, on go-to-market. And that belief becomes part of your investment thesis”.

But this comes with risk. Founders-turned-angels often admit they want to support many of the companies they meet, knowing how painful the journey is. “It’s emotionally hard not to”. Boundaries are critical. Otherwise, you end up over-exposed and over-committed.

Still, many argue, it’s a better use of capital than investing in publicly traded companies. Unlike buying a random tech stock, angel investing allows you to apply your lived knowledge, networks, and operational judgment. “You wouldn’t put your entire pension into it, but as a slice of your portfolio, it makes sense”.

Engaging with Angels

In 2021, in almost any coffee place in major tech hubs, you could have spotted angels looking for their next investment. By contrast, now angels became far more selective, sometimes even elusive. They are more often pushing back on valuation or insisting on customer validation first. But first they need to be found!

There’s a persistent myth that angels sit in closed networks or “secret angel bars” where the next unicorn is quietly auctioned. The reality is much less glamorous: LinkedIn, warm introductions, WhatsApp / Slack groups, and even structured office hours.

Some founder-angels set aside weekly blocks where anyone can book a slot. Others prefer to operate quietly, relying on referrals. Almost none rely on cold inbound, unless the outreach is extraordinarily thoughtful.

But before engaging, what should you consider?

Team above all. Almost every angel we spoke with said the same thing. “Investing early means investing in people”. But it doesn’t mean investing in CVs. Founder – market fit is important (especially as digital health is often first and foremost about execution). However, personality traits such as adaptability and grit were frequently mentioned as a must. Beyond that, founders who understand that go-to-market, not technology, is the hardest part.

Check sizes vary widely. Some angels lean small ($25K–50K), others go up to $100K+, and a select few even beyond. Knowing the right target range matters. Pitching an angel who typically writes $ 25,000 checks for a $1 million lead position is a mismatch.

Angels often specialize, just like VCs. We spoke with many digital health founder-angles who said they are unlikely to back medical devices or biotech companies. A fintech founder may have zero interest in digital health (or not). The same goes for stage and geography. Many want to invest where they can bring connections and credibility.

Signal / Round dynamics – Some angels thrive in the “before VCs” stage, others explicitly wait for institutional validation and some even shared they have a “shortlist of funds I will only invest with”.

Affiliation – some angles are not actually investing their own money (or not just their money) as they are operating as scouts on behalf of funds. Usually, it still means they hold the authority to make the decision, but being aware of these connections can be beneficial.

In this market, usually some validation is required. Many angels said they expect at least some objective data point for traction, even before the first capital is raised. Paying users, pilot contracts, something that grounds the story. “It is way easier to build today, so there is no reason not to have some MVP out there and have some response from your potential users”. More on this below.

What Sets Off Alarm Bells

If team quality is the most significant driver of investment, personality red flags are the fastest way to kill an angel investment.

The most common? Over-naïveté. Especially about timelines and GTM execution. “If a founder says they’ll close a large payer deal in six months, they lost me there”. Founder-Angels know firsthand how hard this game is, and what overoptimism can do to an early-stage company.

Weak communication skills. Not just because “the founder should be the best salesperson of their company” but also because not knowing you don’t communicate well (such as sharing bad presentations, or even have type(o)s in your materials) signals a lack of self-awareness. “A founder who can’t see their own blind spots will miss critical market signals too”.

Then there’s the “too salesy” problem. “Founders who present everything as flawless lose my trust quickly”. Angels expect challenges. They have lived through many of them. In fact, explicitly naming two or three core risks (“This one we know how to solve, this one we’re not sure, this one we need help”) builds more credibility than a glossy pitch with zero cracks.

Finally, ignorance of business models or reimbursement frameworks is a hard stop. In digital health, particularly, you don’t get far without some understanding of how money flows. We got a lot of examples from angels for companies that were terrific at raising capital but when it came down to actually selling their product, no buyer was to be found.

Angels today like:

Angels vs. VCs

Many overlaps can be found between Angels and VCs. However, there are some notable differences (beyond stage and check size) that are worth keeping in mind.

Source of capital. Angels invest their own money. That makes them more personal, flexible, and founder-friendly. Nevertheless, sometimes ‘personal’ can also come with disadvantages (for example, angels who want too frequent touchpoints with the company). So do your dilegence, like when you choose which VC to work with.

Motivations. Many angels invest as much for learning, network, and impact and not ‘just’ for capital gain. For some, it means their tolerance for risk (and losses) can be higher. For other, it is their own money and they are measuring each deal on its on (unlike the portfolio theory of VCs).

Dilution reality. Most angels know they’ll get diluted as they can’t follow pn. Some will try to sell early in secondary transactions to mitigate that; others will have the conviction to ride until the end, expecting the increase in valuation will make that dilution irrelevant.

Limited signal. If a major investor stops supporting a company, it can create a a pretty negative signal. “Something bad must be happening”. Angels seem to skip the signaling issue as their relative check size is too small to ‘mean’ anything (thus also justifying the rationale of a secondary).

Some market observations

The pandemic boom years (2020–22) and ZIRP (zero interest rates, driving more risk-seeking capital) created a very founder-friendly investment environment. One of the implications was that great teams could raise many millions on a CV and a deck.

That era is over.

“Today, expectations are higher”. Yes, even for angels.

Angels want evidence that an idea isn’t just theoretical. “There are so many cost-efficient ways you can test drive your hypothesis with the market in digital health, so meeting a team that asked for your money without doing that is quite concerning”.

And of course, today AI is front and center. When it comes to angel investing, there seems to be some value in differentiating between three buckets of companies:

• AI-first (foundational model builders): high risk, insanely capital-intensive. Probably not angel-appropriate unless capable of writing big checks.
• AI-enabled (apps built on models): more approachable, but execution and defensibility are everything. These seem to be areas where angels will want to spend enough time with the founder before investing to have enough confidence in their ability to deliver. Best example might be working together before.
• AI-enablers (infrastructure/tools): Sometimes less sexy (backend) but can also mean more tangible tech moat. Some of the more “techy” angels we spoke with (former CTOs) shared that these are companies they feel more comfortable with.

Closing Thoughts

Founder-angels sit in an odd space in the market. They aren’t institutions with LP obligations, but they also aren’t hobbyists writing one-off checks. They are peers who’ve lived the startup grind, now recycling that knowledge and capital back into the ecosystem. Whether they’re “pattern-recognizing” correctly or simply projecting their own journeys onto the next generation doesn’t matter as much as the effect: they’ve become an essential early-stage bridge.

In sectors like digital health, where multiple stakeholders are involved in sales cycles and reimbursement can often be irrational and complex, angels can provide more than just initial capital. They can mean a real vote of confidence and a lever down the road.

It’s easy to romanticize founder-angels as uniquely empathetic backers. Some are. Others are just as ruthless as institutions, only with smaller checkbooks. What’s undeniable is that they now play a structural role in how innovation gets seeded.

For founders seeking capital, the implication is clear: don’t treat angel checks as casual money. Treat them diligently and thoughtfully. The next breakthrough in healthtech may well start with a $25K check from someone who once sat in your chair.